Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EBITDA: 2009-2024

Historic EBITDA for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $16.2 million.

  • Gyre Therapeutics' EBITDA rose 63.60% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 115.81%. This contributed to the annual value of $16.2 million for FY2024, which is 124.04% up from last year.
  • Gyre Therapeutics' EBITDA amounted to $16.2 million in FY2024, which was up 124.04% from -$67.2 million recorded in FY2023.
  • Gyre Therapeutics' EBITDA's 5-year high stood at $16.2 million during FY2024, with a 5-year trough of -$87.9 million in FY2021.
  • In the last 3 years, Gyre Therapeutics' EBITDA had a median value of $9.2 million in 2022 and averaged -$14.0 million.
  • As far as peak fluctuations go, Gyre Therapeutics' EBITDA plummeted by 830.52% in 2023, and later spiked by 124.04% in 2024.
  • Over the past 5 years, Gyre Therapeutics' EBITDA (Yearly) stood at -$57.4 million in 2020, then tumbled by 53.21% to -$87.9 million in 2021, then spiked by 110.47% to $9.2 million in 2022, then tumbled by 830.52% to -$67.2 million in 2023, then spiked by 124.04% to $16.2 million in 2024.